• 点赞
  • 评论
  • 收藏

Lifecore Biomedical 2025年第二季度GAAP每股收益$(0.25)优于预期$(0.29),销售额$3260万高于预期$2975万

财报速递01-03

Lifecore Biomedical (NASDAQ:LFCR)报告季度每股亏损$(0.25),优于分析师普遍预期的$(0.29),差异率为13.79%。公司报告季度销售额为$3260万,超过分析师普遍预期的$2975万,差异率为9.59%。与去年同期的$3015万相比,这一销售额增长了8.13%。

以上内容来自Benzinga Earnings专栏,原文如下:

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. The company reported quarterly sales of $32.60 million which beat the analyst consensus estimate of $29.75 million by 9.59 percent. This is a 8.13 percent increase over sales of $30.15 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论

empty
暂无评论
 
 
 
 

热议股票

 
 
 
 
 

7x24